Twist Bioscience (NASDAQ:TWST) Shares Gap Up – Here’s Why

Twist Bioscience Co. (NASDAQ:TWST)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $36.89, but opened at $44.00. Twist Bioscience shares last traded at $40.70, with a volume of 398,303 shares traded.

Wall Street Analyst Weigh In

TWST has been the subject of a number of research reports. Robert W. Baird upped their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research note on Monday, August 5th. Evercore ISI upped their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Barclays decreased their price objective on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. JPMorgan Chase & Co. increased their target price on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a report on Monday, August 5th. Finally, Leerink Partners lifted their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $51.22.

Twist Bioscience Stock Up 12.0 %

The stock’s fifty day simple moving average is $43.90 and its 200 day simple moving average is $46.11. The firm has a market capitalization of $2.42 billion, a PE ratio of -10.61 and a beta of 1.78.

Insider Buying and Selling

In other Twist Bioscience news, SVP Paula Green sold 1,057 shares of Twist Bioscience stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $41.56, for a total transaction of $43,928.92. Following the transaction, the senior vice president now owns 121,013 shares of the company’s stock, valued at $5,029,300.28. The trade was a 0.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Dennis Cho sold 1,507 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $48.00, for a total transaction of $72,336.00. Following the completion of the sale, the insider now directly owns 91,163 shares of the company’s stock, valued at approximately $4,375,824. This trade represents a 1.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 98,118 shares of company stock valued at $4,391,151. 3.92% of the stock is owned by company insiders.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds have recently made changes to their positions in the business. Signaturefd LLC boosted its stake in Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares during the period. EdgeRock Capital LLC bought a new position in shares of Twist Bioscience during the second quarter worth $43,000. Blue Trust Inc. grew its stake in Twist Bioscience by 2,912.8% during the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after acquiring an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new stake in Twist Bioscience in the 2nd quarter valued at $61,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after acquiring an additional 381 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.